<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243864</url>
  </required_header>
  <id_info>
    <org_study_id>866</org_study_id>
    <nct_id>NCT03243864</nct_id>
  </id_info>
  <brief_title>Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis</brief_title>
  <official_title>: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's primary objective is to determine plasma and dialysis fluid concentrations in
      patients prescribed ceftazidime-avibactam as the standard treatment for their infection and
      requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment
      for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics
      of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the
      prescribed dose meets pharmacodynamic targets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">October 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftazidime plasma concentrations</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Avibactam plasma concentrations</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftazidime effluent concentrations</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Avibactam effluent concentrations</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse effects as a measure of safety</measure>
    <time_frame>Days 1-30</time_frame>
    <description>Measure of safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin)</measure>
    <time_frame>At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)</time_frame>
    <description>mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>8-hours</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl)</measure>
    <time_frame>8-hours</time_frame>
    <description>L/hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0 to 8 hours</measure>
    <time_frame>8-hours</time_frame>
    <description>mg*hr/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sieving Coefficient</measure>
    <time_frame>8-hours</time_frame>
    <description>SC</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Renal Failure</condition>
  <condition>Bacterial Infections</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Ceftazidime and Avibactam</arm_group_label>
    <description>Ceftazidime-avibactam pharmacokinetic monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime-avibactam</intervention_name>
    <description>Patients will be started on 2.5 gm IV every 8 hours</description>
    <arm_group_label>Ceftazidime and Avibactam</arm_group_label>
    <other_name>Avycaz</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, effluent fluid from dialysis machine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt; 18 years of age

          -  Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic
             renal failure

          -  documented or suspected infection requiring a prescription for ceftazidime-avibactam

        Exclusion Criteria:

          -  Patients on CRRT &lt; 24 hours

          -  Patients on ceftazidime-avibactam &lt; 24 hours

          -  Patients unable to remain on CRRT for 32 hours continuously without clotting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Rose, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Rose, Pharm.D.</last_name>
    <phone>215-707-8057</phone>
    <email>rosecm@temple.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Mueller, MD</last_name>
    <phone>215-707-1982</phone>
    <email>Daniel.Mueller2@tuhs.temple.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Rose, Pharm.D.</last_name>
      <phone>215-707-8057</phone>
      <email>rosecm@temple.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

